Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen

Shilpa Vishwanath, Fuad M. Baroody, Mohamad Chaaban, Marcella Detineo, Kenneth H. Lasser, Elliot C. Lasser, Robert M. Naclerio

Research output: Contribution to journalLetter

2 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)219-221
Number of pages3
JournalJournal of Allergy and Clinical Immunology
Volume128
Issue number1
DOIs
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Nasal Provocation Tests
Ioxaglic Acid
Sneezing
Intranasal Administration
Anti-Allergic Agents
Seasonal Allergic Rhinitis
Nose
Double-Blind Method
Allergens
Cross-Over Studies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen. / Vishwanath, Shilpa; Baroody, Fuad M.; Chaaban, Mohamad; Detineo, Marcella; Lasser, Kenneth H.; Lasser, Elliot C.; Naclerio, Robert M.

In: Journal of Allergy and Clinical Immunology, Vol. 128, No. 1, 07.2011, p. 219-221.

Research output: Contribution to journalLetter

Vishwanath, Shilpa ; Baroody, Fuad M. ; Chaaban, Mohamad ; Detineo, Marcella ; Lasser, Kenneth H. ; Lasser, Elliot C. ; Naclerio, Robert M. / Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen. In: Journal of Allergy and Clinical Immunology. 2011 ; Vol. 128, No. 1. pp. 219-221.
@article{00448a4b71744bbaa5e8203dd2763cd9,
title = "Topical intranasal ioxaglate meglumine 39.3{\%} and ioxaglate sodium 19.6{\%} (Hexabrix) reduces the acute response to nasal challenge with allergen",
author = "Shilpa Vishwanath and Baroody, {Fuad M.} and Mohamad Chaaban and Marcella Detineo and Lasser, {Kenneth H.} and Lasser, {Elliot C.} and Naclerio, {Robert M.}",
year = "2011",
month = "7",
doi = "10.1016/j.jaci.2011.02.024",
language = "English (US)",
volume = "128",
pages = "219--221",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "1",

}

TY - JOUR

T1 - Topical intranasal ioxaglate meglumine 39.3% and ioxaglate sodium 19.6% (Hexabrix) reduces the acute response to nasal challenge with allergen

AU - Vishwanath, Shilpa

AU - Baroody, Fuad M.

AU - Chaaban, Mohamad

AU - Detineo, Marcella

AU - Lasser, Kenneth H.

AU - Lasser, Elliot C.

AU - Naclerio, Robert M.

PY - 2011/7

Y1 - 2011/7

UR - http://www.scopus.com/inward/record.url?scp=79959844408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959844408&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2011.02.024

DO - 10.1016/j.jaci.2011.02.024

M3 - Letter

VL - 128

SP - 219

EP - 221

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 1

ER -